HC Wainwright Analysts Reduce Earnings Estimates for PTGX

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for shares of Protagonist Therapeutics in a report issued on Wednesday, May 7th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($0.67) per share for the quarter, down from their previous estimate of ($0.65). HC Wainwright has a "Buy" rating and a $80.00 price target on the stock. The consensus estimate for Protagonist Therapeutics' current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Protagonist Therapeutics' Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at $0.93 EPS, FY2025 earnings at ($0.41) EPS, Q1 2026 earnings at $0.03 EPS, FY2026 earnings at ($1.41) EPS, FY2027 earnings at ($1.41) EPS, FY2028 earnings at ($0.30) EPS and FY2029 earnings at $2.86 EPS.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.31. The business had revenue of $28.32 million during the quarter, compared to analysts' expectations of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%.

Other equities research analysts have also recently issued reports about the company. BTIG Research set a $73.00 price objective on Protagonist Therapeutics in a research note on Monday, March 3rd. BMO Capital Markets boosted their price objective on Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. The Goldman Sachs Group lowered their price objective on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating for the company in a research report on Monday, February 24th. Wedbush restated an "outperform" rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a research note on Friday, March 28th. Finally, JPMorgan Chase & Co. upped their target price on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $65.44.

Protagonist Therapeutics Trading Down 2.2%

NASDAQ PTGX traded down $1.00 during trading hours on Monday, reaching $44.27. The company had a trading volume of 910,114 shares, compared to its average volume of 873,882. The stock has a 50-day moving average of $47.09 and a 200 day moving average of $42.66. Protagonist Therapeutics has a 1-year low of $27.00 and a 1-year high of $60.60. The stock has a market capitalization of $2.74 billion, a P/E ratio of 16.64 and a beta of 2.65.

Insider Buying and Selling at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the transaction, the chief executive officer now directly owns 540,260 shares in the company, valued at approximately $20,627,126.80. The trade was a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Asif Ali sold 24,903 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the completion of the sale, the chief financial officer now directly owns 62,821 shares of the company's stock, valued at approximately $3,689,477.33. This trade represents a 28.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,532 shares of company stock worth $3,665,786 over the last 90 days. 5.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Protagonist Therapeutics

Several institutional investors have recently bought and sold shares of the business. Northern Trust Corp raised its position in Protagonist Therapeutics by 1.7% in the 1st quarter. Northern Trust Corp now owns 639,507 shares of the company's stock valued at $30,927,000 after purchasing an additional 10,927 shares during the last quarter. Brooklyn Investment Group bought a new stake in shares of Protagonist Therapeutics during the first quarter valued at approximately $68,000. Algert Global LLC raised its holdings in Protagonist Therapeutics by 5.3% during the 1st quarter. Algert Global LLC now owns 18,665 shares of the company's stock worth $903,000 after purchasing an additional 945 shares during the last quarter. State of New Jersey Common Pension Fund D bought a new stake in Protagonist Therapeutics during the 1st quarter worth about $2,599,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Protagonist Therapeutics during the 1st quarter worth about $135,000. Institutional investors own 98.63% of the company's stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.